Sharon L. Gardner MD

Pediatric Hematology & Oncology•New York, NY

Associate Professor, Pediatrics, New York University School of Medicine

Join to View Full Profile

317 E 34th StNew York, NY 10016
Phone+1 212-263-8400

Education & Training

New York Presbyterian Hospital (Cornell Campus)Fellowship, Pediatric Hematology/Oncology, 1989 - 1992
Tower Health/St. Christopher's Hospital for ChildrenResidency, Pediatrics, 1986 - 1989
Drexel University College of MedicineClass of 1986

Certifications & Licensure

NY State Medical License 1989 - 2025
PA State Medical License 1987 - 2002
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

Top Doctors: New York Metro Area Castle Connolly, 2013-2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Super Doctor SuperDoctors.com

Clinical Trials

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Brain Cancer Start of enrollment: 2000 Oct 01
Completed
Phase 1
Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma Start of enrollment: 2003 Nov 01
Completed
Phase 2, Phase 3
High-Dose Chemotherapy Plus Autologous Stem Cell Transplantation Compared With Intermediate-Dose Chemotherapy Plus Autologous Stem Cell Transplantation With or Without Isotretinoin in Treating Young Patients With Recurrent High-Grade Gliomas Start of enrollment: 2004 Oct 01
Completed
Phase 3
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors Start of enrollment: 2005 Oct 01
Completed
Phase 2
Study of Peptide Vaccination With Tumor Associated Antigens Mixed With Montanide in Patients With CNS Tumors Start of enrollment: 2009 Jul 01
Completed
Phase 1
Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG) Start of enrollment: 2011 Sep 01
Terminated
Phase 2
ONC201 in Pediatric H3 K27M Gliomas Start of enrollment: 2018 Jan 25
TERMINATED
PHASE1
Roles: Principal Investigator, Contact
Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas
AVAILABLE
Roles: Contact, Principal Investigator
HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors
ACTIVE_NOT_RECRUITING
PHASE4
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

3 citations
Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma.
Yazmin Odia, Carl Koschmann, Nicholas A Vitanza, Peter de Blank, Dolly Aguilera
Neuro-Oncology. 2024-05-03
11 citations
ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma.
Isabel Arrillaga-Romany, Sharon L Gardner, Yazmin Odia, Dolly Aguilera, Joshua E Allen
Journal of Clinical Oncology. 2024-05-01
1 citations
Final report of the phase II NEXT/CNS-GCT-4 trial: GemPOx followed by marrow-ablative chemotherapy for recurrent intracranial germ cell tumors.
Margaret Shatara, Megan Blue, Joseph Stanek, Yin A Liu, Daniel M Prevedello
Neuro-Oncology Practice. 2024-04-01

Lectures

ONC201 in previously-irradiated pediatric H3 K27M-mutant glioma.
2019 ASCO Annual Meeting - 6/1/2019

Professional Memberships

American Society of Clinical Oncology - ASCO
Member